Patents by Inventor David J. Morgans, Jr.

David J. Morgans, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11952376
    Abstract: The invention relates to compounds of formula (I): or a salt thereof, wherein R1, G, L1, L2, L3, and Y are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are inhibitors of one, or both of, ?v?1 integrin and ?v?6 integrin that are useful for treating fibrosis such as in nonalcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).
    Type: Grant
    Filed: October 18, 2021
    Date of Patent: April 9, 2024
    Assignee: PLIANT THERAPEUTICS, INC.
    Inventors: Jacob Cha, Manuel Muñoz, Maureen Reilly, Nicole Cooper, Katerina Leftheris, David J. Morgans, Jr., Timothy Hom, Yajun Zheng, Christopher Bailey, Darren Finkelstein
  • Publication number: 20240018105
    Abstract: Disclosed are a series of compounds or their tautomers having a general structure represented by Formula Ia or Ib and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising said compounds or tautomers or pharmaceutically acceptable salts thereof. Further disclosure relates to a method of treating a disease or condition associated with iron dysregulation or dysfunctional iron homeostasis, comprising administering to a subject in need thereof a therapeutically effective amount of Formula Ia or Ib compounds or tautomers or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: October 16, 2020
    Publication date: January 18, 2024
    Applicant: Kinesid Therapeutics, Inc.
    Inventors: Jianhua Chao, Stanley J. Hollenbach, Michael C. Holmes, Douglas M. Matje, Nicholas M. Snead, Gustave Bergnes, Kevin T. Mellem, David J. Morgans, Jr, Walter S. Won
  • Publication number: 20230181546
    Abstract: The invention relates to methods of therapy using compounds of formula (I) and formula (II): or a salt thereof, wherein R1, R2, R10, R11, R12, R13, R14, R15, R16, q and p are as described herein. Compounds of formula (II) and pharmaceutical compositions thereof are integrin inhibitors that are useful in therapy for a condition, for example, caused by or associated with an infectious agent, shock, pancreatitis, or trauma. The condition can include one or more of pulmonary fibrosis associated with rheumatoid arthritis or progressive familial intrahepatic cholestasis (PFIC).
    Type: Application
    Filed: April 30, 2021
    Publication date: June 15, 2023
    Inventors: Eric LEFEBVRE, Scott TURNER, Jacob CHA, Chengguo DONG, Timothy HOM, Lan JIANG, Katerina LEFTHERIS, Hui LI, David J. MORGANS, Jr., Manuel MUNOZ, Maureen REILLY, Yajun ZHENG, Kraig ANDERSON
  • Publication number: 20220185779
    Abstract: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
    Type: Application
    Filed: October 22, 2021
    Publication date: June 16, 2022
    Inventors: Bradley Paul MORGAN, Alex MUCI(Deceased), Pu-Ping LU, Todd TOCHIMOTO, David J. MORGANS, JR., Erica Anne KRAYNACK
  • Publication number: 20220144829
    Abstract: The invention relates to compounds of formula (I): or a salt thereof, wherein R1, G, L1, L2, L3, and Y are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are inhibitors of one, or both of, ?v?1 integrin and ?v?6 integrin that are useful for treating fibrosis such as in nonalcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).
    Type: Application
    Filed: October 18, 2021
    Publication date: May 12, 2022
    Inventors: Jacob CHA, Manuel MUÑOZ, Maureen REILLY, Nicole COOPER, Katerina LEFTHERIS, David J. MORGANS, JR., Timothy HOM, Yajun ZHENG
  • Patent number: 11180494
    Abstract: The invention relates to compounds of formula (I): or a salt thereof, wherein R1, G, L1, L2, L3, and Y are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are inhibitors of one, or both of, ?v?1 integrin and ?v?6 integrin that are useful for treating fibrosis such as in nonalcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).
    Type: Grant
    Filed: October 8, 2019
    Date of Patent: November 23, 2021
    Assignee: Pliant Therapeutics, Inc.
    Inventors: Jacob Cha, Manuel Munoz, Maureen Reilly, Nicole Cooper, Katerina Leftheris, David J. Morgans, Jr., Timothy Hom, Yajun Zheng
  • Publication number: 20210198203
    Abstract: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
    Type: Application
    Filed: March 12, 2021
    Publication date: July 1, 2021
    Inventors: Bradley Paul Morgan, Alex Muci, Pu-Ping Lu, Erica Anne Kraynack, Todd Tochimoto, David J. Morgans, JR.
  • Patent number: 10975034
    Abstract: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: April 13, 2021
    Assignee: CYTOKINETICS, INC.
    Inventors: Bradley Paul Morgan, Alex Muci, Pu-Ping Lu, Erica Anne Kraynack, Todd Tochimoto, David J. Morgans, Jr.
  • Publication number: 20200352942
    Abstract: The invention relates to dosage forms for daily administration of compounds of formula (A) and formula (I): or a salt thereof, wherein R1, R2, R10, R11, R12, R13, R14, R15, R16, q and p are as described herein. Compounds of formula (A), formula (I), and pharmaceutical compositions thereof are ?v?6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).
    Type: Application
    Filed: April 8, 2020
    Publication date: November 12, 2020
    Inventors: Jacob CHA, Chengguo DONG, Timothy HOM, Lan JIANG, Katerina LEFTHERIS, Hui LI, David J. MORGANS, JR., Manuel MUNOZ, Maureen REILLY, Yajun ZHENG, Martin DECARIS, Scott TURNER
  • Patent number: 10793564
    Abstract: The invention relates to compounds of formula (A) and formula (I): or a salt thereof, wherein R1, R2, R10, R11, R12, R13, R14, R15, R16, q and p are as described herein. Compounds of formula (A), formula (I), and pharmaceutical compositions thereof are ?v?6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: October 6, 2020
    Assignee: PLIANT THERAPEUTICS, INC.
    Inventors: Jacob Cha, Chengguo Dong, Timothy Hom, Lan Jiang, Katerina Leftheris, Hui Li, David J. Morgans, Jr., Manuel Munoz, Maureen Reilly, Yajun Zheng
  • Patent number: 10766899
    Abstract: Provided are methods of preparing compounds of Formula 201:
    Type: Grant
    Filed: April 7, 2014
    Date of Patent: September 8, 2020
    Assignee: CYTOKINETICS, INCORPORATED
    Inventors: Bradley P. Morgan, David J. Morgans, Jr., Alex Muci
  • Publication number: 20200109141
    Abstract: The invention relates to compounds of formula (I): or a salt thereof, wherein R1, G, L1, L2, L3, and Y are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are inhibitors of one, or both of, ?v?1 integrin and ?v?6 integrin that are useful for treating fibrosis such as in nonalcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).
    Type: Application
    Filed: October 8, 2019
    Publication date: April 9, 2020
    Inventors: Jacob CHA, Manuel MUNOZ, Maureen REILLY, Nicole COOPER, Katerina LEFTHERIS, David J. MORGANS, JR., Timothy HOM, Yajun ZHENG
  • Publication number: 20190352267
    Abstract: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
    Type: Application
    Filed: July 2, 2019
    Publication date: November 21, 2019
    Inventors: Bradley Paul Morgan, Alex Muci, Pu-Ping Lu, Erica Anne Kraynack, Todd Tochimoto, David J. Morgans, JR.
  • Publication number: 20190276449
    Abstract: The invention relates to compounds of formula (A) and formula (I): or a salt thereof, wherein R1, R2, R10, R11, R12, R13, R14, R15, R16, q and p are as described herein. Compounds of formula (A), formula (I), and pharmaceutical compositions thereof are ?v?6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).
    Type: Application
    Filed: March 7, 2019
    Publication date: September 12, 2019
    Inventors: Jacob CHA, Chengguo DONG, Timothy HOM, Lan JIANG, Katerina LEFTHERIS, Hui LI, David J. MORGANS, JR., Manuel MUNOZ, Maureen REILLY, Yajun ZHENG
  • Patent number: 10385023
    Abstract: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: August 20, 2019
    Assignee: CYTOKINETICS, INC.
    Inventors: Bradley Paul Morgan, Alex Muci, Pu-Ping Lu, Erica Anne Kraynack, Todd Tochimoto, David J. Morgans, Jr.
  • Publication number: 20180305316
    Abstract: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
    Type: Application
    Filed: June 28, 2018
    Publication date: October 25, 2018
    Inventors: Bradley Paul Morgan, Alex Muci, Pu-Ping Lu, Erica Anne Kraynack, Todd Tochimoto, David J. Morgans, JR.
  • Patent number: 10035770
    Abstract: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: July 31, 2018
    Assignee: Cytokinetics, Incorporated
    Inventors: Bradley Paul Morgan, Alex Muci, Pu-Ping Lu, Erica Anne Kraynack, Todd Tochimoto, David J. Morgans, Jr.
  • Publication number: 20170267638
    Abstract: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
    Type: Application
    Filed: April 6, 2017
    Publication date: September 21, 2017
    Inventors: Bradley Paul Morgan, Alex Muci, Pu-Ping Lu, Erica Anne Kraynack, Todd Tochimoto, David J. Morgans, JR.
  • Patent number: 9643925
    Abstract: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
    Type: Grant
    Filed: August 27, 2015
    Date of Patent: May 9, 2017
    Inventors: Bradley Paul Morgan, Alex Muci, Pu-Ping Lu, Erica Anne Kraynack, Todd Tochimoto, David J. Morgans, Jr.
  • Publication number: 20160115133
    Abstract: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
    Type: Application
    Filed: August 27, 2015
    Publication date: April 28, 2016
    Inventors: Bradley Paul Morgan, Alex Muci, Pu-Ping Lu, Erica Anne Kraynack, Todd Tochimoto, David J. Morgans, JR.